8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Chen C, Yan Z-S Ma Y-Q, Ding H-M

Bioeffects Seen

Authors not listed · 2023

Share:

Database error: This kidney cancer drug study contains no EMF research content.

Plain English Summary

Summary written for general audiences

This clinical trial studied 421 kidney cancer patients comparing a combination immunotherapy treatment (toripalimab plus axitinib) against standard chemotherapy (sunitinib). The combination therapy significantly extended progression-free survival from 9.8 months to 18.0 months and doubled response rates from 31% to 57%.

Why This Matters

I notice there appears to be a database error - this study examines kidney cancer treatments, not electromagnetic field exposure. The research focuses on pharmaceutical interventions for renal cell carcinoma and contains no EMF-related findings. This appears to be a misclassified entry that doesn't belong in an EMF research database. The study's focus on immune checkpoint inhibitors and tyrosine kinase inhibitors for cancer treatment has no connection to electromagnetic field health effects or exposure assessment.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2023). Chen C, Yan Z-S Ma Y-Q, Ding H-M.
Show BibTeX
@article{chen_c_yan_z_s_ma_y_q_ding_h_m_ce3181,
  author = {Unknown},
  title = {Chen C, Yan Z-S Ma Y-Q, Ding H-M},
  year = {2023},
  doi = {10.1016/j.annonc.2023.09.3108},
  
}
DOI: 10.1016/j.annonc.2023.09.3108PubMed: 37872020

Quick Questions About This Study

This appears to be a database classification error. The study examines pharmaceutical cancer treatments with no electromagnetic field content or relevance to EMF health research.
No, these are pharmaceutical drugs administered intravenously and orally for kidney cancer treatment. The study contains no electromagnetic field exposure or EMF-related measurements.
None whatsoever. This is purely a pharmaceutical clinical trial comparing drug efficacy for renal cell carcinoma with no electromagnetic field components or considerations.
While hospitals use EMF-emitting equipment, this study focused solely on drug effectiveness and safety outcomes without measuring or considering electromagnetic field exposure.
No, this study provides no EMF-related data or insights. It belongs in oncology research databases, not electromagnetic field health research collections.